Investigating the effect of citicoline administration on cognitive impairment, social interactions, and speech status in autistic children A clinical trial study

Investigating the effect of citicoline administration on cognitive impairment, social interactions, and speech status in autistic children at pre-school and post-school ages

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241029063537N2

Enrollment

Registered

2025-06-12

Start date

2025-07-23

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism. Autistic disorder

Interventions

Intervention 1: Intervention group: In the intervention group, the drug citicoline cytidine-5'-diphosphocholine (CDP-choline) will be administered for 5 weeks in addition to the usual treatment for au

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: Consent to participate in the research project Age 2 to 18 years No neurological, cognitive, speech, emotional, psychiatric, and movement disorders unrelated to autism No epilepsy, seizures, or vision or hearing problems No use of any psychiatric medication

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the research project Autistic patients who are over 18 years old Autistic patients who are involved in neurological and psychiatric diseases that affect cognitive status, concentration, speech and motor behaviors

Design outcomes

Primary

Measure	Time frame
Cognitive Impairment, social interactions, and speech status. Timepoint: The beginning and end of the study. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Stereotypical behavior score. Timepoint: The beginning and end of the study. Method of measurement: Gilliam Autism Rating Scale, Third Edition.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHouman Parsaie

Semnan University of Medical Sciences

houman70parsaie@yahoo.com+98 23 3365 4162

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026